New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AVEO;ODP;RAD;AMAT;NAVB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 23, 2015
13:16 EDTRADPharmacies, PBMs seen as potential buyers after Omnicare said to explore sale
Subscribe for More Information
12:08 EDTRADLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Larsen, along with Mary Ptacek, VP of Pharmaceutical Strategies Group and Ruth Krystopolski, EVP of Sanford Health, discuss the 2016-2017 Pharmacy Benefit Managers selling season and which PBMs are poised to gain share, the impact of WBAís growth plans, recent M&A activity and biosimilars on an Analyst/Industry conference call to be held on April 24 at 2 pm.
07:36 EDTRADUBS estimates Omnicare buyer would need to pay $95 per share
Subscribe for More Information
April 22, 2015
08:02 EDTNAVBNavidea: Data for Menocept CD206 demonstrates potential to impact KS tumor cells
Navidea Biopharmaceuticals reported data at the American Association of Cancer Research Annual Meeting 2015 demonstrating that the Manocept molecule selectively binds to, and is continuously internalized by, tumor-associated macrophages and Kaposiís sarcoma, or KS, tumor cells in a preclinical model. Preliminary results from a clinical study also demonstrated that a single, subcutaneous injection of Technetium Tc 99m tilmanocept, an FDA-approved Manocept-based imaging agent, detects and localizes in KS tumors and the lymph nodes involved in draining the KS tumor fields. Collectively, the data demonstrate the potential for Manocept-based molecules to be used therapeutically to treat Kaposiís sarcoma. Manocept is designed to target CD206, which is expressed on TAMs and KS tissue. Modulation, including killing or modification of macrophage and KS expression profiles, represents a potential for a paradigm-shifting immunotherapeutic strategy.
08:00 EDTRADRite Aid weakness a buying opportunity, says Cowen
Cowen said to add to Rite aid positions on the recent pullback as the reason for the weakness is the receding of a takeout premium, which was not in the firm's investment thesis to begin with. The firm sees strong underlying fundamentals and strong returns from its store remodeling program, which is still in its early innings. Cowen reiterated its Outperform rating and $12 price target on Rite Aid shares.
07:01 EDTAVEOAveo Oncology names Keith Ehrlich as CFO
Subscribe for More Information
April 20, 2015
19:21 EDTAMATSemiconductor equipment stocks rising after Lam Research Q3 results
Subscribe for More Information
18:48 EDTAMATOn The Fly: After Hours Movers
UP AFTER EARNINGS: Lam Research (LRCX), up 9.2%... Fortinet (FTNT), up 9%. ALSO HIGHER: Lumber Liquidators (LL), up 2% after being initiated with a Buy, $45 target at Cantor... Geron (GERN), up 2.2% after being initiated with an Outperform at Oppenheimer... Applied Materials (AMAT), up 1.6% after Lam Research reported quarterly results. DOWN AFTER EARNINGS: Sanmina (SANM), down 10.5%... IBM (IBM), down marginally... Rambus (RMBS), down 3.7%.
09:31 EDTRADRite Aid names Steve Rempel as SVP, Chief Information Officer
Rite Aid Corporation announced that Steve Rempel, a highly experienced information technology executive, has been named Rite Aidís senior vice president and chief information officer. In this position, Rempel will have responsibility for all aspects of the companyís technology and information operations, including computer systems, network infrastructure, telecommunications and data security as well as the continued development and execution of Rite Aidís immediate and long-term information technology strategy. Rempel will report to Frank Vitrano, Rite Aidís senior executive vice president and chief administrative officer.
07:30 EDTAMATApplied Materials added to Franchise Picks list at Jefferies
Jefferies added Applied Materials (AMAT) to its Franchise Picks list with the stock down 14% year-to-date. The firm attributes the pullback to concerns around tool reuse, and notes it still expects foundry capital spending to increase amid "increased process complexity and competition." Jefferies' work indicates TSMC's (TSM) and Intel's (INTC) capex cuts were driven by market share losses rather than innovation in tool reuse. It keeps a Buy rating on AMAT with a $29 price target.
07:04 EDTAVEOAveo Pharmaceuticals announces presentation of AV-380 preclinical data
Subscribe for More Information
April 16, 2015
11:07 EDTAMATTSMC capex cut not worrisome for semi equipment makers, says Summit Research
Subscribe for More Information
10:36 EDTAMATApplied Materials drifts lower, levels to watch
The shares are down nearly 3% to $21.87 as Intel's (INTC) capex cuts weigh on the stock and its peers. At current price next support is at $21.36. Resistance is at $22.39.
April 15, 2015
06:41 EDTAMATCiti recommends Applied Materials, Lam after Intel capex cut
Subscribe for More Information
April 14, 2015
17:04 EDTAMATSemiconductor equipment stocks lower after Intel cuts FY15 CapEx view
Subscribe for More Information
11:07 EDTRADStocks with call strike movement; EBAY RAD
Subscribe for More Information
10:34 EDTRADOptions with decreasing implied volatility
Subscribe for More Information
07:58 EDTRADRite Aid has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO John Standley on April 21 at 1 pm.
April 13, 2015
11:28 EDTODPStarboard CEO says Staples, Office Depot merger 'likely to go through'
Says confident the potential merger will pass anti-trust scrutiny. Jeff Smith is speaking on CNBC.
10:33 EDTRADOptions with decreasing implied volatility
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use